Crispr Therapeutics AG is trading at $54.27 (-4.71%) today, giving back a portion of its June 4 rally during a wider market retreat.
- The decline aligns with a broad risk-off session that has seen the Nasdaq drop 1.67% as technology stocks face pressure from semiconductor weakness.
- There are no clear company-specific catalysts for the move, which appears to be driven by profit-taking following recent gains.